These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 31138367)

  • 1. Discovery and Structure-Resistance Relationship Study of New Thieno[2,3-
    Xiao KJ; Zuo WQ; Xu Y; Tao X; Yu LT; Wang NY
    Pharmazie; 2019 Jun; 74(6):321-325. PubMed ID: 31138367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel HCV inhibitors: synthesis and biological activity of 6-(indol-2-yl)pyridine-3-sulfonamides targeting hepatitis C virus NS4B.
    Zhang X; Zhang N; Chen G; Turpoff A; Ren H; Takasugi J; Morrill C; Zhu J; Li C; Lennox W; Paget S; Liu Y; Almstead N; Njoroge FG; Gu Z; Komatsu T; Clausen V; Espiritu C; Graci J; Colacino J; Lahser F; Risher N; Weetall M; Nomeir A; Karp GM
    Bioorg Med Chem Lett; 2013 Jul; 23(13):3947-53. PubMed ID: 23683597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of 2-(4-sulfonamidophenyl)-indole 3-carboxamides as potent and selective inhibitors with broad hepatitis C virus genotype activity targeting HCV NS4B.
    Zhang N; Turpoff A; Zhang X; Huang S; Liu Y; Almstead N; Njoroge FG; Gu Z; Graci J; Jung SP; Pichardo J; Colacino J; Lahser F; Ingravallo P; Weetall M; Nomeir A; Karp GM
    Bioorg Med Chem Lett; 2016 Jan; 26(2):594-601. PubMed ID: 26652483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 6-(Azaindol-2-yl)pyridine-3-sulfonamides as potent and selective inhibitors targeting hepatitis C virus NS4B.
    Chen G; Ren H; Zhang N; Lennox W; Turpoff A; Paget S; Li C; Almstead N; Njoroge FG; Gu Z; Graci J; Jung SP; Colacino J; Lahser F; Zhao X; Weetall M; Nomeir A; Karp GM
    Bioorg Med Chem Lett; 2015 Feb; 25(4):781-6. PubMed ID: 25613678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and characterization of a replicon-based phenotypic assay for assessing HCV NS4B from clinical isolates.
    Rajyaguru S; Yang H; Martin R; Miller MD; Mo H
    Antiviral Res; 2013 Nov; 100(2):328-36. PubMed ID: 24013002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Characterization and In Vivo Efficacy of GSK8853, a Small-Molecule Inhibitor of the Hepatitis C Virus NS4B Protein.
    Pouliot JJ; Thomson M; Xie M; Horton J; Johnson J; Krull D; Mathis A; Morikawa Y; Parks D; Peterson R; Shimada T; Thomas E; Vamathevan J; Van Horn S; Xiong Z; Hamatake R; Peat AJ
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6539-50. PubMed ID: 26259798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of AP80978, a novel small-molecule inhibitor of hepatitis C virus replication that targets NS4B.
    Dufner-Beattie J; O'Guin A; O'Guin S; Briley A; Wang B; Balsarotti J; Roth R; Starkey G; Slomczynska U; Noueiry A; Olivo PD; Rice CM
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3399-410. PubMed ID: 24709254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and structure-activity relationships study of novel thieno[2,3-b]pyridine analogues as hepatitis C virus inhibitors.
    Wang NY; Zuo WQ; Xu Y; Gao C; Zeng XX; Zhang LD; You XY; Peng CT; Shen Y; Yang SY; Wei YQ; Yu LT
    Bioorg Med Chem Lett; 2014 Mar; 24(6):1581-8. PubMed ID: 24529869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of imidazo[2,1-b]thiazole HCV NS4B inhibitors exhibiting synergistic effect with other direct-acting antiviral agents.
    Wang NY; Xu Y; Zuo WQ; Xiao KJ; Liu L; Zeng XX; You XY; Zhang LD; Gao C; Liu ZH; Ye TH; Xia Y; Xiong Y; Song XJ; Lei Q; Peng CT; Tang H; Yang SY; Wei YQ; Yu LT
    J Med Chem; 2015 Mar; 58(6):2764-78. PubMed ID: 25710739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Drug Discovery for Anti-hepatitis C Virus Targeting NS4B.
    Wang Z; Chen X; Wu C; Xu H; Liu H
    Curr Top Med Chem; 2016; 16(12):1362-71. PubMed ID: 26585935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of PTC725, an orally bioavailable small molecule that selectively targets the hepatitis C Virus NS4B protein.
    Gu Z; Graci JD; Lahser FC; Breslin JJ; Jung SP; Crona JH; McMonagle P; Xia E; Liu S; Karp G; Zhu J; Huang S; Nomeir A; Weetall M; Almstead NG; Peltz SW; Tong X; Ralston R; Colacino JM
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3250-61. PubMed ID: 23629699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of spirocyclic compounds as HCV replication inhibitors by targeting viral NS4B protein.
    Tai VW; Garrido D; Price DJ; Maynard A; Pouliot JJ; Xiong Z; Seal JW; Creech KL; Kryn LH; Baughman TM; Peat AJ
    Bioorg Med Chem Lett; 2014 May; 24(10):2288-94. PubMed ID: 24731273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a novel class of potent HCV NS4B inhibitors: SAR studies on piperazinone derivatives.
    Kakarla R; Liu J; Naduthambi D; Chang W; Mosley RT; Bao D; Steuer HM; Keilman M; Bansal S; Lam AM; Seibel W; Neilson S; Furman PA; Sofia MJ
    J Med Chem; 2014 Mar; 57(5):2136-60. PubMed ID: 24476391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of a dengue NS4B inhibitor originating from an HCV small molecule library.
    Hernandez-Morales I; Geluykens P; Clynhens M; Strijbos R; Goethals O; Megens S; Verheyen N; Last S; McGowan D; Coesemans E; De Boeck B; Stoops B; Devogelaere B; Pauwels F; Vandyck K; Berke JM; Raboisson P; Simmen K; Lory P; Van Loock M
    Antiviral Res; 2017 Nov; 147():149-158. PubMed ID: 29037976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and structure-activity relationships of novel imidazo[4,5-c]pyridine derivatives as potent non-nucleoside inhibitors of hepatitis C virus NS5B.
    Liu M; Xu Q; Guo S; Zuo R; Hong Y; Luo Y; Li Y; Gong P; Liu Y
    Bioorg Med Chem; 2018 May; 26(9):2621-2631. PubMed ID: 29681484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computer-aided identification, synthesis and evaluation of substituted thienopyrimidines as novel inhibitors of HCV replication.
    Bassetto M; Leyssen P; Neyts J; Yerukhimovich MM; Frick DN; Brancale A
    Eur J Med Chem; 2016 Nov; 123():31-47. PubMed ID: 27474921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction networks of hepatitis C virus NS4B: implications for antiviral therapy.
    Li S; Yu X; Guo Y; Kong L
    Cell Microbiol; 2012 Jul; 14(7):994-1002. PubMed ID: 22329740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C replication inhibitors that target the viral NS4B protein.
    Miller JF; Chong PY; Shotwell JB; Catalano JG; Tai VW; Fang J; Banka AL; Roberts CD; Youngman M; Zhang H; Xiong Z; Mathis A; Pouliot JJ; Hamatake RK; Price DJ; Seal JW; Stroup LL; Creech KL; Carballo LH; Todd D; Spaltenstein A; Furst S; Hong Z; Peat AJ
    J Med Chem; 2014 Mar; 57(5):2107-20. PubMed ID: 23544424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of replication efficacy of the hepatitis C virus replicon Con1 by site-directed mutagenesis of an NS4B aminoterminal basic leucine zipper.
    Welker MW; Susser S; Welsch C; Perner D; Füller C; Kronenberger B; Herrmann E; Zeuzem S; Sarrazin C
    J Viral Hepat; 2012 Nov; 19(11):775-83. PubMed ID: 23043384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PTC725, an NS4B-Targeting Compound, Inhibits a Hepatitis C Virus Genotype 3 Replicon, as Predicted by Genome Sequence Analysis and Determined Experimentally.
    Graci JD; Jung SP; Pichardo J; Lahser F; Tong X; Gu Z; Colacino JM
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7060-7066. PubMed ID: 27620477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.